Table 2. Clinical activity of targeted therapy in BRAF‐mutant metastatic non‐small cell lung cancer.

^aResponses did not require second post‐baseline scan for confirmation.

^bDisease control rate is defined as complete response + partial response + stable disease.

^cIncludes patients with a response of stable disease at week 8 for vemurafenib or at least 12 weeks for dabrafenib and dabrafenib + trametinib.

^dHalf of responses were ongoing at data cutoff.

Abbreviations: DOR, duration of response; NR, not reported; PFS, progression‐free survival.